Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug safety guidance

This article was originally published in The Tan Sheet

Executive Summary

FDA has abandoned its original idea for a Drug Watch Web site and will instead post drug safety information on a Drug-Specific Information Web site on the Center for Drug Evaluation and Research home page, the agency announces in a final guidance released March 2. Drug sponsors will be notified that emerging drug safety data will be posted at least 24 hours before the information is communicated, the agency adds. The guidance, which outlines how FDA plans to communicate drug safety information to the public, follows a May 2005 draft guidance, which proposed having Drug Watch list drugs considered as having significant emerging safety risks. However, many comments received by the agency stated that such a name might create confusion with the current MedWatch program. The Consumer Healthcare Products Association stated in its own comments on Drug Watch that information should be posted only after its significance had been "fully determined" (1"The Tan Sheet" Aug. 15, 2005, p. 3)...

You may also be interested in...

FDA Drug Watch System May "Confuse" Consumers In Proposed Form - CHPA

FDA should include drug safety information on its new Drug Watch system only after a review has "fully determined the significance of the information, causal or otherwise," according to the Consumer Healthcare Products Association

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts